Inhibrx Biosciences, Inc. INBX Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s long-term debt?
- Inhibrx Biosciences, Inc. (INBX) reported long-term debt of $174.99M in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s long-term debt changed year-over-year?
- Inhibrx Biosciences, Inc.'s long-term debt increased by 77.4% year-over-year, from $98.65M to $174.99M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s long-term debt?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s long-term debt has grown at a -30.3% compound annual growth rate (CAGR), from $206.97M to $100.56M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.